Policy/Advocacy News

Home/Policy/Advocacy News

Editorial: Unacceptable poison pill in tobacco tax initiative

By the Editorial Board Apr 24, 2016 It pains us to reverse this newspaper’s support for what seemed like a worthy Missouri constitutional amendment, but we cannot advocate a clear attempt to deceive voters with what now appears to be a Trojan horse measure. We’re talking about a ballot initiative that aimed to raise $305 million

Tobacco companies bankrolling rival efforts to hike Missouri’s tobacco tax

By JO MANNIES • 4.21.16 For all the talk about increasing Missouri’s tobacco tax to provide more money for education and transportation, the state’s two dueling tobacco-tax proposals appear caught in a longstanding dispute that has nothing to do with their objectives. Tobacco companies are the chief donors to both initiative-petition campaigns that seek to

Frequently Asked Questions & Answers

        Why does Missouri Cures oppose the 2016 Early Childhood Health and Education Amendment ballot initiative promoted by a group called Raise Your Hand for Kids (RYH4K)? Missouri Cures does not take a position on the merits of a tobacco tax to support early childhood education. Our opposition to the initiative is

Missouri Cures opposes hijacked ballot initiative

Since the Missouri Stem Cell Research and Cures Constitutional Amendment was passed by voters in 2006, anti-research activists have continued to find ways to reverse the medical and economic gains. Their latest attempt has been to insert language in an otherwise attractive ballot proposal, "Raise Your Hand for Kids," that would fund early childhood education with increased

Amendment made human cloning illegal in Missouri

February 19, 2015 Regarding the letter "Abortion proponents try to redefine when life begins" (Feb. 10): The statement that the Amendment 2 campaign in 2006 legalized human cloning is absolutely incorrect. Amendment 2 guarantees that all research taking place on the federal level will remain legal in Missouri, keeping our outstanding research institutions in the

NIH Will No Longer Require Special Review for U.S. Gene Therapy Trials

Science Insider, by Jocelyn Kaiser ~ May 22, 2014 In a milestone for the field of gene therapy, the National Institutes of Health (NIH) will no longer subject all proposed gene therapy clinical trials to review by a special federal advisory committee. “Given the progress in the field, I am confident that the existing regulatory